ERBB2 and ductal breast carcinoma in situ: The overall HER-2 positivity rate for DCIS in this study was only 55%, reflecting the deliberate inclusion of a higher proportion of non-high-grade DCIS tumours in this study (associated with a lower HER-2 positivity) to investigate COX-2 expression across nuclear grades.